About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

JoAnn Scatina, Ph.D.

JoAnn Scatina, Ph.D., is a Scientific Fellow, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to this role, Dr. Scatina spent three years as a Preclinical Consultant to Deerfield. Before this, she was Senior Vice President, Preclinical Development at Lycera Pharmaceuticals for eight years. Prior to Lycera, Dr. Scatina spent twenty-six years at Wyeth in roles of increasing responsibility, with her most recent position being Vice President, Drug Metabolism. Dr. Scatina holds a B.A. in Microbiology from Rutgers University and a Ph.D. in Pharmacology and Toxicology from University of Medicine and Dentistry of New Jersey.